Medicina interna
Especialidad
Susana Laura
Monge Corella
Publications dans lesquelles il/elle collabore avec Susana Laura Monge Corella (12)
2018
-
Barriers to health care services for migrants living with HIV in Spain
European Journal of Public Health, Vol. 28, Núm. 3, pp. 451-457
2017
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy
HIV Medicine, Vol. 17, Núm. 9, pp. 653-661
-
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663
2015
-
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2014
-
Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: A study in a Spanish cohort
HIV Medicine, Vol. 15, Núm. 2, pp. 86-97
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
AIDS, Vol. 28, Núm. 16, pp. 2461-2473
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2012
-
Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class
Clinical Microbiology and Infection, Vol. 18, Núm. 11